


Journal Pre-proof

Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group

Antonio Oliver, Estrella Rojo-Molinero, Jorge Arca-Suarez, Yeşim Beşli, Pierre Bogaerts, Rafael Cantón, Cansu Cimen, Peter D. Croughs, Olivier Denis, Christian G. Giske, Tíscar Graells, Te-Din Daniel Huang, Bogdan I. Iorga, Onur Karatuna, Béla Kocsis, Andreas Kronenberg, Carla López-Causapé, Surbhi Malhotra-Kumar, Luis Martínez Martínez, Annarita Mazzariol, Sylvain Meyer, Thierry Naas, Daan W. Notermans, Jesús Oteo-Iglesias, Torunn Pedersen, Mateja Pirš, Patricia Poeta, Laurent Poirel, Spyros Pournaras, Arnfinn Sundsfjord, Dora Szabó, Arjana Tambić-Andrašević, Rossitza Vatcheva-Dobrevska, Astra Vitkauskienė, Katy Jeannot, on behalf of ESGARS-ISARPAE members



PII: S1198-743X(23)00634-1

DOI: <https://doi.org/10.1016/j.cmi.2023.12.026>

Reference: CMI 3513

To appear in: *Clinical Microbiology and Infection*

Received Date: 13 October 2023

Revised Date: 18 December 2023

Accepted Date: 25 December 2023

Please cite this article as: Oliver A, Rojo-Molinero E, Arca-Suarez J, Beşli Y, Bogaerts P, Cantón R, Cimen C, Croughs PD, Denis O, Giske CG, Graells T, Daniel Huang T-D, Iorga BI, Karatuna O, Kocsis B, Kronenberg A, López-Causapé C, Malhotra-Kumar S, Martínez LM, Mazzariol A, Meyer S, Naas T, Notermans DW, Oteo-Iglesias J, Pedersen T, Pirš M, Poeta P, Poirel L, Pournaras S, Sundsfjord A, Szabó D, Tambić-Andrašević A, Vatcheva-Dobrevska R, Vitkauskienė A, Jeannot K, on behalf of ESGARS-ISARPAE members, *Pseudomonas aeruginosa* antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group, *Clinical Microbiology and Infection*, <https://doi.org/10.1016/j.cmi.2023.12.026>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published

in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

***Pseudomonas aeruginosa* antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group**

Antonio Oliver¹, Estrella Rojo-Molinero¹, Jorge Arca-Suarez², Yeşim Beşli³ Pierre Bogaerts⁴, Rafael Cantón⁵, Cansu Cimen⁶, Peter D Croughs⁷, Olivier Denis⁸, Christian G. Giske⁹, Tíscar Graells¹⁰, Te-Din Daniel Huang⁴, Bogdan I. Iorga¹¹, Onur Karatuna¹², Béla Kocsis¹³, Andreas Kronenberg¹⁴, Carla López-Causapé¹, Surbhi Malhotra-Kumar¹⁵, Luis Martínez Martínez¹⁶, Annarita Mazzariol¹⁷, Sylvain Meyer¹⁸, Thierry Naas¹⁹, Daan W Notermans²⁰, Jesús Oteo-Iglesias²¹, Torunn Pedersen²², Mateja Pirš²³, Patricia Poeta²⁴, Laurent Poirel²⁵, Spyros Pournaras²⁶, Arnfinn Sundsfjord^{22, 27}, Dora Szabó^{13, 28}, Arjana Tambić-Andrašević²⁹, Rossitza Vatcheva-Dobrevska³⁰, Astra Vitkauskienė³¹ and Katy Jeannot³² on behalf of ESGARS-ISARPAE members.

¹Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

²Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

³Department of Medical Microbiology, Amerikan Hastanesi, Istanbul, Turkey.

⁴National Center for Antimicrobial Resistance in Gram-, CHU UCL Namur, Yvoir, Belgium.

⁵Servicio de Microbiología, Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

⁶Institute for Medical Microbiology and Virology, University of Oldenburg, Oldenburg, Germany. Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

⁷Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.

⁸Department of Microbiology, CHU Namur site-Godinne, Université Catholique de Louvain, Yvoir, Belgium; Ecole de Santé Publique, Université Libre de Bruxelles, Brussels, Belgium.

⁹Department of Clinical Microbiology, Karolinska University Hospital; Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, Solna, Stockholm, Sweden.

¹⁰Department of Neurobiology, Care Sciences and Society (NVS), Division of Family Medicine and Primary Care, Karolinska Institutet, Huddinge, Stockholm, Sweden.

¹¹Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, Gif-sur-Yvette, France.

¹²EUCAST Development Laboratory, Clinical Microbiology, Central Hospital, Växjö, Sweden.

¹³Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary.

¹⁴Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

¹⁵Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerpen, Belgium.

¹⁶Unidad de Microbiología, Hospital Universitario Reina Sofía, Departamento de Química Agrícola, Edafología y Microbiología, Universidad de Córdoba, e Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

¹⁷Microbiology and Virology Section, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.

¹⁸Inserm UMR 1092 and Université of Limoges, Limoges, France.

¹⁹Laboratoire Associé du Centre National de Référence de la Résistance aux Antibiotiques: Entérobactéries Résistantes aux Carbapénèmes, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Équipe INSERM ReSIST, Faculté de Médecine.

²⁰Centre for Infectious Disease Control. National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

²¹Reference and Research Laboratory in Resistance to Antibiotics and Infections Related to Healthcare, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

²²Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.

²³Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

²⁴MicroART-Microbiology and Antibiotic Resistance Team, Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal.; Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, Lisboa, Portugal; Veterinary and Animal Research Centre (CECAV), University

of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal; Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Vila Real, Portugal.

²⁵Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.

²⁶Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

²⁷Research Group on Host-Microbe Interactions, Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.

²⁸Human Microbiota Study Group, Semmelweis University-Eötvös Lóránd Research Network, Budapest, Hungary.

²⁹Department of Clinical Microbiology, University Hospital for Infectious Diseases, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia.

³⁰Department of Microbiology and Virology, University Hospital 'Tsaritsa Yoanna- ISUL' Sofia, Bulgaria.

³¹Department of Laboratory Medicine, Faculty of Medicine, Medical Academy, Lithuanian University of Health Science, Kaunas, Lithuania.

³²Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Besançon, Besançon, France; Laboratoire associé du Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, France; Chrono-environnement UMR 6249, CNRS, Université Franche-Comté, Besançon, France.

Abstract

Scope: *Pseudomonas aeruginosa*, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of *P. aeruginosa* to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extended spectrum β -lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of *P. aeruginosa* resistance mechanisms, especially for the extensively drug-resistant (XDR)/difficult to treat resistance (DTR) international high-risk epidemic lineages, and how the recently approved β -lactams and β -lactam/ β -lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles. **Methods:** To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) launched the “Improving Surveillance of Antibiotic-Resistant *Pseudomonas aeruginosa* in Europe” (ISARPAE) initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance (JPIAMR) network call and included a panel of over 40 researchers from 18 European Countries. Thus, an ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members. **Questions addressed in the position paper:** To provide an update on (i) the emerging resistance mechanisms to classical and novel antipseudomonal agents, with a particular focus on β -lactams, (ii) the susceptibility profiles associated with the most relevant β -lactam resistance mechanisms, (iii) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles and (iv) the globally expanding XDR/DTR high-risk lineages and their association with transferable resistance mechanisms. **Implication:** The evidence presented herein can be used for coordinated epidemiological surveillance and decision-making at the European and global level.

Scope and context

Pseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired and chronic infections associated with significant morbidity and mortality (1). Accordingly, *P. aeruginosa* infections are estimated to be associated with over 300,000 annual deaths and are at the top of the WHO priority list for the need for research and development of new antibiotics (2,3). This growing threat results from the extraordinary capacity of this pathogen to develop antimicrobial resistance through chromosomal mutations and from the increasing prevalence of transferable resistance determinants, particularly those encoding carbapenemases or extended-spectrum β -lactamases (ESBLs) (4,5). Combinations of such mechanisms lead to concerning and complex resistance profiles, defined by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) as multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR), while the Infectious Diseases Society of America/National Institutes of Health (IDSA/NIH) defines them as difficult-to-treat resistance (DTR) (6,7). *P. aeruginosa* possesses a non-clonal epidemic population structure, comprising a limited number of widespread lineages, selected from a background of numerous rare and unrelated genotypes recombined at high frequency (8). In fact, several surveys have provided evidence for the existence of XDR/DTR international high-risk clonal lineages, which have disseminated in hospitals worldwide (9–11). Beyond classical molecular epidemiology analysis and phenotypic assessment of resistance mechanisms, whole genome sequencing (WGS) studies are providing pertinent information to elucidate the complex and evolving resistome of MDR/XDR/DTR *P. aeruginosa* high-risk lineages (12–15).

The recent introduction of novel β -lactam/ β -lactamase inhibitor combinations (BLBLIs) such as ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam or imipenem/relebactam and the siderophore-cephalosporin cefiderocol, has contributed to mitigate, to some extent, the problem of XDR/DTR *P. aeruginosa* (16–19). These agents exhibit enhanced stability against intrinsically- and chromosomally-encoded β -lactam resistance

mechanisms in *P. aeruginosa*, such as overexpression of the AmpC β -lactamase encoding gene, overproduction of efflux pumps, or inactivation of the OprD porin. However, they are not exempt from resistance development through emerging mutational mechanisms (20–24). These include modification (quantitative or qualitative) of AmpC hydrolytic activity or efflux pumps substrate specificity, which were observed shortly after their introduction into clinical practice. Moreover, BLBLIs are not currently effective against the most potent transferable carbapenemases, particularly class B or metallo- β -lactamases [MBLs] such as VIM, IMP or NDM enzymes (25). Consequently, use of BLBLIs could lead to the selection of these concerning resistance mechanisms (26). Besides the approved options, several novel BLBLIs are undergoing clinical trials (25). These agents, such as aztreonam/avibactam, cefepime/zidebactam or cefepime/taniborbactam, promise additional therapeutic choices and the ability to counteract already established resistance mechanisms (17).

The introduction of novel BLBLIs is therefore significantly broadening the range of treatment options for XDR/DTR *P. aeruginosa* infections(17,25). However, this expansion will also have a major impact on antimicrobial resistance epidemiology, including both novel and existing mutation-driven resistance mechanisms, transferable resistance determinants and epidemic high-risk clonal lineages. A comprehensive understanding of *P. aeruginosa* resistance mechanisms and susceptibility profiles, especially of the XDR/DTR high-risk lineages, and how these promising novel agents may affect resistance mechanisms and, in turn, the definition of resistance profiles, is needed to have a common ground and may help to anticipate and coordinate epidemiological information in the future.

Questions addressed in the position paper

To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) launched the “Improving Surveillance of Antibiotic-Resistant *Pseudomonas aeruginosa* in Europe” (ISARPAE) initiative in 2022, supported by the Joint programming initiative on

antimicrobial resistance (JPIAMR) network. Thus, this position document from the ESGARS-ISARPAE Group aimed to provide an update on (i) the emerging resistance mechanisms to classical and novel anti-pseudomonal agents, with a particular focus on β -lactams, (ii) the susceptibility profiles associated with the most relevant β -lactam resistance mechanisms, (iii) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles, and (iv) the globally expanding XDR/DTR high-risk lineages and their association with transferable β -lactamases.

Methods

All ESGARS-ESCMID members were contacted and invited to participate in the ISARPAE initiative, according to their interest and experience in the topic. This resulted in the generation of a panel of over 40 researchers from 18 European countries in June 2022. The panel agreed the above objectives to be addressed in the position paper and AO and ERM prepared a first draft of the document after extensive literature review helped by other panel members. In July 2023 the first draft of the document was sent to all ISARPAE members for revision and specific contributions, leading to a second draft version that was extensively revised and discussed during an ISARPAE hybrid (onsite/online) meeting that took place at Hospital Son Espases-IdISBa (Mallorca, Spain) on September 8th 2023. The third resulting draft was then sent for review by panel members and final version of the document was approved in October 6th 2023.

Emerging resistance mechanisms to classical and novel anti-pseudomonal agents and associated susceptibility profiles

Table 1 shows the main categories and agents showing antipseudomonal activity, including those recently introduced and those that will be clinically available in the next few years, and presents the respective mutation-driven and horizontally-acquired resistance mechanisms. On the other hand, **Figure 1** shows the susceptibility profiles associated with the most relevant β -lactam resistance mechanisms in *P. aeruginosa*.

Pseudomonas aeruginosa β -lactam resistome

Pseudomonas aeruginosa is intrinsically resistant to aminopenicillins, alone and combined with clavulanic acid, as well as to most of the older cephalosporins, notably including the third generation cephalosporin cefotaxime, due to the production of an inducible AmpC β -lactamase (27). Moreover, AmpC plays a major role in the basal resistance level (MIC) of *P. aeruginosa* to the potent AmpC inducer imipenem. On the other hand, the constitutive expression of the efflux pump MexAB-OprM plays a major role in the basal resistance level to most other β -lactams except imipenem.

The most frequent mutation-driven resistance mechanism to classical antipseudomonal penicillins (such as piperacillin) and cephalosporins (such as ceftazidime or cefepime) is the overproduction of the chromosomal cephalosporinase AmpC, involving a large number of genes belonging to cell-wall recycling regulatory pathways (28). Notably, among these genes, the mutational inactivation of *dacB*, encoding the nonessential penicillin-binding protein (PBP) PBP4 and *ampD*, encoding a N-acetyl-muramyl-L-alanine amidase, have been found to be the most frequent cause of derepressed *ampC* gene expression, and subsequent broad-spectrum β -lactam resistance (29,30). Additionally, specific point mutations causing a conformational change in the transcriptional regulator AmpR, leading to *ampC* upregulation and resistance to broad-spectrum β -lactams, have been noted among clinical strains. These mutations include the D135N amino acid replacement, described in several species (28) and the G154H mutation linked to the disseminated MDR/XDR ST175 high-risk lineage (14). Mutation of several other genes, including those encoding amidases (AmpDh2 and AmpDh3), PBPs, such as PBP5 or PBP7, lytic transglycosylases, MPL, or NuoN have also been shown to enhance *ampC* expression, either alone or in combination with other mutations. Nevertheless, their impact on β -lactam resistance among clinical strains still needs to be further analysed (28).

In addition to *ampC* overexpression, recent studies have revealed that increased levels of β -lactam resistance, involving the novel BLBLIs ceftolozane/tazobactam and ceftazidime/avibactam, may result from mutations leading to the modification of the catalytic center of AmpC, currently mainly

occurring in (up to 10-15%) patients treated with these agents (20,31–33). Additional studies identified diverse AmpC variants associated with high-level resistance to BLBLIs, including the above mentioned ceftolozane/tazobactam and ceftazidime/avibactam, in a small proportion (around 1%) of clinical *P. aeruginosa* isolates (34). Over 500 variants of those AmpC enzymes, also called *Pseudomonas* Derived Cephalosporinases (PDC), have been described so far, including those associated with increased ceftolozane/tazobactam and ceftazidime/avibactam resistance. Moreover, some of these variants, such as those showing the L320P substitution, have a significant impact on cefiderocol MICs, but only a marginal effect on susceptibility to ceftolozane/tazobactam and ceftazidime/avibactam (35). An updated database of PDC variants is maintained at IdISBa and is freely available at (<https://arpbigidisba.com/pseudomonas-aeruginosa-derived-cephalosporinase-pdc-database/>) and at the Beta-Lactamase Data Base (<http://www.bldb.eu/BLDB.php?prot=C#PDC>) (36). Typically, the strains producing these AmpC variants show collateral susceptibility to imipenem (decreased MICs) and also to antipseudomonal penicillins such as piperacillin. Additionally, resistance development to ceftolozane/tazobactam and/or ceftazidime/avibactam may involve mutations leading to the structural modification of narrow spectrum OXA-2 and OXA-10 acquired oxacillinases (20,37,38). Interestingly, these mutations may lead to collateral susceptibility to meropenem. Thus, imipenem/relebactam, and to a lesser extent, cefiderocol, meropenem/vaborbactam and the novel combinations under development cefepime/zidebactam and cefepime/taniborbactam might be interesting options to treat infections by strains that have developed ceftolozane/tazobactam and/or ceftazidime/avibactam resistance through mutations in AmpC or OXA-2/10 (39).

Horizontally-acquired β -lactamase genes are obviously a major source of resistance, including to the novel β -lactams and BLBLI (**Figure 1**). An extensive revision of the nature and prevalence of the different horizontally-acquired β -lactamases detected in *P. aeruginosa* is beyond the scope of this document. However, globally, MBLs are arguably the most frequent carbapenemases in *P. aeruginosa*, but very large geographical differences in prevalence and nature have been documented (40,41). At European level, VIM, and particularly VIM-2,

are likely the most frequently reported enzymes, but with major differences across different countries, and with an increasing prevalence of NDM enzymes (42,43). Moreover, GES class A carbapenemases variants such as GES-5 are also increasingly reported in European countries (43,44). Classical antipseudomonal penicillins, cephalosporins and carbapenems lack significant activity and should be avoided against strains producing class A or MBL carbapenemases, even if MICs close to the clinical breakpoints are obtained for piperacillin/tazobactam, cefepime or even carbapenems for some VIM-2-producing isolates (12). Moreover, the production of MBLs is a frequent mechanism of resistance to ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam (26). However, with a few exceptions such as some NDM variants, cefiderocol retains activity due to its higher stability against hydrolysis and efficient uptake through the iron transport systems (45). The combination of aztreonam with avibactam may also be a useful future alternative for MBL producing strains, particularly when additionally hyperproducing AmpC and/or coproducing acquired class A enzymes (46,47). Likewise, the novel combinations under development cefepime/zidebactam and cefepime/taniborbactam also remain active. The underlying mechanism for cefepime/zidebactam activity against MBL producing strains is based on the fact that zidebactam has direct antipseudomonal activity by targeting PBP2, and therefore provides synergy with β -lactams targeting PBP3 such as the cephalosporins (48). On the other hand, the activity of cefepime/taniborbactam relies on the fact that taniborbactam inhibits MBL hydrolytic activity, except for IMPs (49). In addition to these three antimicrobials (cefiderocol, cefepime/zidebactam and cefepime/taniborbactam), ceftazidime/avibactam, and to a lower extent imipenem/relebactam and meropenem/vaborbactam show activity against producers of Ambler class A carbapenemases (such as GES-5 and KPCs) (50–52). However, the frequent concomitant OprD deficiency and/or MexAB-OprM overexpression limits the activity of imipenem/relebactam and meropenem/vaborbactam against clinical *P. aeruginosa* strains producing class A carbapenemases (52,53). On the other hand, resistance development to ceftazidime/avibactam caused by the selection of mutations within the catalytic site of KPC and GES enzymes has been described (54–56). Interestingly, these mutations restore carbapenem susceptibility (if the strain is not oprD deficient)

leading to an ESBL phenotype (54). In addition to those of classes A and B, a few cases of class D carbapenemase production have been reported in *P. aeruginosa*, including the epidemic dissemination OXA-198 in a hospital from Belgium (57).

In addition to β -lactamases, there is growing evidence on the role of target modification in *P. aeruginosa* β -lactam resistance. Of particular relevance are the mutations in *ftsI*, encoding PBP3, an essential class B PBP with transpeptidase activity (58). Indeed, data from cystic fibrosis (CF) patients (59,60), epidemic high-risk clonal lineages (12,14) as well as from *in vitro* studies (61) have shown that PBP3 is under strong mutational pressure, with specific mutations in this PBP contributing to β -lactam resistance development. R504C/H and F533L mutations are those being most commonly reported and located within the protein domains implicated in the formation and stabilization of the inactivating complex β -lactam-PBP3 (62). Moreover, these specific mutations have been documented to emerge *in vivo* during chronic respiratory infection in CF patients (59,60) and upon exposure to meropenem (61), aztreonam (63) and ceftazidime (64) *in vitro*. However, the detailed effect of PBP3 mutations on β -lactam resistance phenotypes needs to be further investigated using isogenic strains. Likewise, despite unique polymorphisms having been detected in some clinical strains for other PBPs, their potential role in β -lactam resistance still needs to be experimentally determined. Also noteworthy are the specific PBP2 mutations involved in resistance to zidebactam (65), that obviate the β -lactam enhancer activity of this BLI.

Other relevant components of the β -lactam mutational resistome are the genes encoding OprD and efflux pumps. The inactivation of OprD is known to be the most frequent imipenem resistance mechanisms in *P. aeruginosa* (66,67). OprD inactivation typically results from indels or nonsense mutations, including the Q142X mutation, characteristic of the widespread ST175 high-risk clonal lineage (14). Additionally, some amino-acid replacements have been associated with OprD-driven resistance, particularly in the CF setting (68). However, it should be noted that the presence of OprD inactivating mutations has also been identified in some carbapenem-susceptible isolates (69). On the other hand, imipenem resistance may also result from repression of *oprD*

caused by mutations in the MexEF-OprN efflux pump regulators (*mexS/T*) or the ParRS two-component system (70). Overexpression of MexAB-OprM, caused by mutation of several genes involved in its regulation (*mexR*, *nalC* or *nalD*) increases MICs of most β -lactams including meropenem but not imipenem, whereas overexpression of genes encoding MexXY (*mexZ*, *parRS*, *amgS* mutations) is involved in cefepime resistance (70)

Efflux pumps may also play a major role in resistance to the novel BLBLIs, not only because of their capacity to extrude the β -lactam components but, particularly, for their capacity to accommodate their partner β -lactamase inhibitor. Indeed MexAB-OprM overexpression plays a role in resistance to ceftazidime/avibactam, aztreonam/avibactam, cefepime/zidebactam, imipenem/relebactam, and meropenem/vaborbactam (65,71–73). Likewise, MexXY overexpression should also impact cefepime combinations with zidebactam or taniborbactam (65). Moreover, mutations leading to the modification of the substrate recognition domain of the efflux pump MexCD-OprJ have been shown to drive ceftolozane/tazobactam resistance development *in vivo* (23)

Additionally, another potentially relevant mutational β -lactam resistance mechanism is the selection of large [up to 600 kb] deletions affecting specific parts of the chromosome (61,64). Although the basis of the conferred resistance phenotype still needs to be further clarified, these mutants can be recognized by the characteristic brown pigment (pyomelanine) caused by the deletion of one of the included genes, *hmgA*, coding for a homogentisate-1,2-dioxygenase. These deletions has been documented in both *in vitro* evolved β -lactam-resistant mutants and CF isolates (61,74). However, the deletion of *hmgA* is not responsible for the resistance phenotype, which could be linked to the deletion of another of the affected genes, *galU*. This gene codes for a UDP-glucose pyrophosphorylase involved in the synthesis of the lipopolysaccharide (LPS) core. Indeed, analysis of transposon mutant libraries has revealed that inactivation of *galU* increases the MICs of ceftazidime and meropenem (75,76).

Lastly, specific cefiderocol resistance development mechanisms involve the selection of mutations in iron uptake systems, particularly in TonB-

dependent receptors such as *piuA/piuC*, *pirA/pirR* or *fptA* [pyochelin receptor] (35). Among these, mutations seem to be particularly frequent in *piuC*, an iron-dependent oxygenase involved in the expression of the adjacent *piuA* [or its homolog *piuD* depending on the strain] iron receptor. On the other hand, mutations in the *fptA* gene, despite being frequent, do not seem to have a direct significant impact on cefiderocol MICs, and thus selection might reflect adaptive mutations for growing in the presence of cefiderocol.

***Pseudomonas aeruginosa* aminoglycoside resistome**

Primary aminoglycoside resistance is typically linked to the production of horizontally-acquired aminoglycoside modifying enzymes, including acetyltransferases, adenylyltransferases and phosphoryltransferases, frequently co-transferred with ESBLs or carbapenemases (77). The specific pattern of aminoglycoside resistance depends on the specific enzymes involved, with amikacin showing an overall higher activity than tobramycin (78). However, the more recently described transferable 16S rRNA methylases, which modify the cellular target of aminoglycosides, are further concerning since they confer resistance to all clinically available members of this antibiotic family and are also cotransferred with ESBLs or carbapenemases (79–81).

On the other hand, the development of resistance to aminoglycosides has been particularly linked to the overexpression of genes encoding the MexXY-OprM system upon some mutations in the regulatory machinery. Indeed, mutational overexpression of this pump, mainly caused by *mexZ*, *amgS*, or *parRS* mutations, is very frequent among clinical isolates, from both CF patients and nosocomial infections (82,83). Moreover, recent studies show that the epidemic high-risk clone ST175 hyperproduces MexXY due to a specific mutation in *mexZ* (G195E) (14). However, recent data suggests that the aminoglycoside mutational resistome extends far beyond MexXY hyperproduction, and high-level resistance may result from the accumulation of multiple mutations. The involvement of several novel resistance determinants has been documented (84–86). Among them, is noteworthy *fusA1*, coding for the elongation factor G. Indeed, specific *fusA1* mutations have been linked to

aminoglycoside resistance *in vitro* (4,86) and among clinical strains, particularly from CF patients (4,60,87–89). Moreover, the implication of *fusA1* mutations in aminoglycoside resistance has been demonstrated through site-directed mutagenesis (90).

***Pseudomonas P. aeruginosa* fluoroquinolone resistome**

Fluoroquinolone resistance in *P. aeruginosa* is primarily driven by mutational mechanisms. The fluoroquinolone mutational resistome generally includes specific missense mutations in DNA gyrase (*gyrA* and/or *gyrB*) and topoisomerase IV (*parC* and/or *parE*) Quinolone Resistance-Determining Regions (QRDRs) (13,91). High-level fluoroquinolone resistance in *P. aeruginosa* high-risk lineages is nearly universal, and typically involves combinations of mutations in GyrA T83 and ParC S87 (12)QRDR mutations involved in fluoroquinolone resistance in CF might be more variable (60). It is also well-known that the mutational overexpression of efflux pumps modulates fluoroquinolone resistance [Table 1]. While the overexpression of MexAB-OprM and MexXY-OprM is globally frequent among clinical strains, its contribution to clinical fluoroquinolone resistance is likely to be modest (91). On the other hand, the mutational overproduction of MexEF-OprN or MexCD-OprJ is associated with clinical fluoroquinolone resistance. Although their prevalence has been considered low, except in the settings of CF chronic infections, recent data show that it might be higher than expected (68). Lastly, the transferable quinolone resistance determinant QnrVC has also been reported, linked to some epidemic strains producing acquired carbapenemases such as ST175 and ST244 (92,93).

***Pseudomonas aeruginosa* polymyxin resistome**

Due to its limited efficacy, toxicity and high ECOFF values (4 mg/L), colistin is not considered an optimal treatment for wild-type *P. aeruginosa*, at least in monotherapy [www.eucast.org]. Moreover, whereas the prevalence of polymyxin [colistin and polymyxin B] resistance is still globally low (<5%), it has

increased in the last years because of the frequent use of these last-resource antibiotics for the treatment of MDR/XDR/DTR nosocomial and CF isolates, particularly in countries with no access to novel BLBLIs (94). Polymyxin resistance results most frequently from the modification of the LPS caused by the addition of a 4-amino-4-deoxy-L-arabinose moiety in the lipid A structure (95,96). The involved mutations are frequently located in the PmrAB or PhoPQ two-component regulators, which lead to the activation of the *arnBCADTEF* operon (97). More recent studies have revealed that mutations in the ParRS two-component regulator, not only produce polymyxin resistance due to the activation of the *arnBCADTEF* operon, but also lead to a MDR phenotype determined by the hyperproduction of MexXY and the repression of *oprD* (98). Moreover, two additional two-component regulators, ColRS and CprRS, have also been determined to be involved in colistin resistance (99). The analysis of colistin resistance mechanisms among clinical strains is not always straightforward, since the presence of mutations in these two-component regulators is not always associated with clinical colistin resistance, probably denoting partial complementation between the different regulators (60,99,100). Moreover, recent *in vitro* evolution assays have revealed the implication of additional mutations in high level colistin resistance, facilitated by the emergence of *mutS* deficient mutator (phenotypes such as those occurring in LptD, LpxC or MigA (101). On the other hand, the role of phosphoethanolamine modification of LPS in *P. aeruginosa* seems marginal, including both, that are driven by intrinsic *eptA* gene expression (102) as well as that are driven by transferable determinants (103).

***Pseudomonas aeruginosa* fosfomycin resistome**

Although not classified as an antipseudomonal agent (ECOFF of 256 mg/L), fosfomycin has been considered in the last decade as a potentially useful antibiotic in urinary tract infections and as combined therapy for MDR/XDR/DTR *P. aeruginosa* in other infection sites (104). However, spontaneous mutation rates for fosfomycin resistance are high and the mechanism involved is typically the mutational inactivation of *glpT*, coding for a glycerol-3-phosphate permease required for fosfomycin uptake (105,106).

Mutations in *glpT* are also frequently found among MDR/XDR/DTR strains (107). Certain specific mutations, like T211P, have become fixed in some widespread lineages as described for ST175 (14)

Definitions of resistance profiles in *Pseudomonas aeruginosa*

According to established recommendations by ECDC (6) the MDR profile is defined as resistance to at least one agent in at least three of eight antibiotic categories. These categories include antipseudomonal penicillins + β -lactamase inhibitor combinations (ticarcillin/clavulanate, piperacillin/tazobactam), antipseudomonal cephalosporins (ceftazidime and cefepime), monobactams (aztreonam), antipseudomonal carbapenems (imipenem, meropenem, doripenem), fluoroquinolones (ciprofloxacin, levofloxacin), aminoglycosides (gentamicin, tobramycin, amikacin, netilmicin), polymyxins (colistin, polymyxin B) and fosfonic acids (fosfomycin). The XDR profile is defined as resistance to at least one agent in all antibiotic classes except one or two. Likewise, PDR profile is defined as resistance to all agents in the eight antibiotic categories. The eighth category (fosfonic acids, fosfomycin) included in the ECDC recommendations should be likely not considered, given the lack of current EUCAST clinical breakpoints. Likewise, the inclusion of gentamicin as antipseudomonal agents is questionable according to current EUCAST breakpoints, and the activity of ticarcillin/clavulanate likely not comparable to that of piperacillin/tazobactam in *P. aeruginosa*. On the other hand, the DTR (difficult to treat resistance) profile is defined according to IDSA/NIH recommendations as resistance to all first line (classical) agents: antipseudomonal penicillins + β -lactamase inhibitor combinations, cephalosporins, monobactams, carbapenems and fluoroquinolones (7). Thus, if fosfomycin is not considered, all DTR isolates would meet the XDR criteria, since they are resistant to at least five of seven categories, but not the other way around.

However, neither the ECDC or IDSA/NIH definitions take into consideration the novel β -lactams and BLBLIs. The inclusion of these novel agents is challenging, starting by grouping them into meaningful “categories”

since their properties, spectrum and mechanisms of resistance show similarities but also marked differences. As shown in **Table 1**, at least 5 novel categories could be considered to include the novel β -lactams already approved: fifth generation antipseudomonal cephalosporins + classical β -lactamase inhibitors (ceftolozane/tazobactam), antipseudomonal cephalosporins + diazabicyclooctanes β -lactamase inhibitors (ceftazidime/avibactam), antipseudomonal carbapenems + diazabicyclooctanes β -lactamase inhibitors (imipenem/relebactam), antipseudomonal carbapenems + boronic acid β -lactamase inhibitors (meropenem/vaborbactam) and siderophore antipseudomonal cephalosporins (cefiderocol). Additionally, there are at least three further classes to be considered in the future if the corresponding antibiotics are approved: monobactams + diazabicyclooctanes β -lactamase inhibitors (aztreonam/avibactam), antipseudomonal cephalosporins+ diazabicyclooctanes β -lactamase and PBP2 inhibitors (cefepime/zidebactam) and antipseudomonal cephalosporins + boronic acid β -lactamase inhibitors including MBLs (cefepime/taniborbactam).

Within the framework of the ECDC definitions, these novel categories could potentially align with MDR implying resistance to at least three classes (of up to 13), XDR indicating resistance to all but one or two and PDR indicating resistance to all. Regarding DTR definition, it would imply resistance to all the novel β -lactams approved. However, the practical application of this definition is likely to encounter challenges due to limited access to these antibiotics for treatment and to the capacity to perform antimicrobial susceptibility testing in several countries. Moreover, the classification of the resistance profiles for the novel agents under development into clinical SIR categories will need to consider PK/PD data, not yet available in some cases, in addition to existing phenotypic and genomic information.

Update on *Pseudomonas aeruginosa* high-risk lineages and their association with transferable β -lactamases

In a recent review (10), according to their prevalence, global spread and association with MDR/XDR/DTR profiles, and specially with concerning horizontally-acquired β -lactamases such as ESBLs and carbapenemases, the worldwide top ten *P. aeruginosa* high-risk lineages were established to be, by order of relevance, ST235, ST111, ST233, ST244, ST357, ST308, ST175, ST277, ST654 and ST298. **Figure 2** shows updated information for these top ten high-risk lineages, including their virulence profile (presence of the genes coding the type III secretion system exotoxins ExoS and/or ExoU), worldwide distribution and association with acquired carbapenemases from key publications in the last three years (40–42,93,108–112). Particularly noteworthy is the expansion of KPC enzymes in several of these lineages (ST233, ST277 and ST654 in addition to the previous detection in ST235, ST111 and ST244), followed by NDM (ST244 and ST357 in addition to ST235, ST233, ST308 and ST654). Moreover, coproduction of various carbapenemases is not infrequent among those lineages (43). Besides these top ten lineages, a few others have gained relevance in the last few years, including globally expanding ST309, associated with the production of VIM-2, ST773 linked to NDM-1, or ST463 associated with the production of KPC-2, particularly in China (113–118).

Concluding remarks and future challenges

P. aeruginosa infections rank among the foremost global resistance threats, associated with significant morbidity and mortality. *P. aeruginosa* resistance mechanisms and epidemiology are complex and ever-evolving, with a significant impact on novel and forthcoming β -lactams. The interplay between novel antibiotics and resistance is notably challenging, as certain mechanisms can lead to cross-resistance to multiple agents, while others may confer collateral susceptibility to relevant antipseudomonals such as carbapenems. The global dissemination of XDR/DTR high-risk lineages are also a major challenge, particularly when coupled with increased virulence and capacity to acquire exogenous resistance elements as documented for ST235 (11). In this sense, a recent nation-wide survey of *P. aeruginosa* susceptibility profiles and resistance genomics has revealed in one hand a significant generalized

decrease of resistance rates and XDR/DTR profiles in Spain in the last five years, but in the other, a significant increase in the proportion of the concerning carbapenemase-producing ST235 high-risk lineage (44).

Therefore, there is a major need for establishing comprehensive resistance surveillance initiatives, integrating both phenotypic and genomic data, as well as metadata. However, our current capacity to predict the susceptibility profiles and emerging high-risk clonal lineages from genomic sequences still needs to be improved, potentially through the incorporation of machine learning, knowledge-based approaches, or so-called artificial intelligence tools (43,119,120). Nevertheless, current achievable surveillance strategies at European level should at least integrate: (1) monitoring of concerning high-risk lineages (particularly ST235); (2) analyses of resistance prevalence trends to recently introduced agents (like the novel BLBLIs) in addition to classical antipseudomonals; (3) monitoring of strains producing horizontally-acquired resistance mechanisms (particularly carbapenemases and ESBLs); and (4) monitoring of noteworthy chromosomal resistance mechanisms such as the AmpC (PDC) derivatives involved in resistance to the novel BLBLIs. Likewise, in this scenario, antimicrobial stewardship and infection control are of paramount importance. Nevertheless, these aspects are equally challenging and should be guided by rapid diagnostics and antimicrobial susceptibility testing, including the detection of resistance mechanisms and specific high-risk clonal lineages (121). Thus, efforts should also be directed to the implementation and scaling of personalized precision medicine that allows us to establish early targeted treatments and specific epidemiological control measures adapted to the strain/mechanism involved.

Conflict of interests

AO received grants, consulting fees and honoraria for lectures from MSD, Shionogi, Pfizer and Wockhardt. ERM received honoraria for lectures from Menarini and Shionogi. JAS received honoraria for lectures from Shionogi. RC received grants and honoraria for lectures from MSD, Menarini and Shionogi. PDC received grants from MSD and Shionogi. All other authors declare no conflict of interests

Authors contributions.

All authors agreed the questions to be addressed in the position paper. AO and ERM drafted a first version of the document that was extensively revised by all other authors.

Acknowledgements

This work was done under the auspices of the European Study Group on Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

Funding

This work was supported by an EU JPIAMR Grant (ISARPAE). AO, CLC, SMK, AT and DS are supported by the EU Horizon 2020 research and innovation program (952491-AmReSu). AO, ERM, JAS, CLC, RC and JOI are supported by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU through the Centers for network research I Personalized and precision medicine grant (MePRAM Project, PMP22/00092). BK was supported by János Bolyai Research Scholarship (BO/00286/22/5) of the Hungarian Academy of Sciences. PP is supported by the projects UIDP/00772/2020 and LA/P/0059/2020 funded by the Portuguese Foundation for Science and Technology (FCT).

References

1. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections. *Clin Microbiol Rev.* 2019 ;32(4).
2. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet.* 2022 Feb 12 ;399(10325):629–55.
3. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis.* 2018 Mar 1 ;18(3):318–27.
4. López-Causapé C, Cabot G, Del Barrio-Tofiño E, Oliver A. The Versatile Mutational Resistome of *Pseudomonas aeruginosa*. *Front Microbiol.* 2018;9:685.
5. Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing *Pseudomonas aeruginosa* -an emerging challenge. *Emerg Microbes Infect.* 2022 ;11(1):811–4.
6. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012 ;18(3):268–81.
7. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Rebecca Prevots D, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. *Clin Infect Dis.* 2018 ;67(12):1803–14.
8. Pelegri AC, Palmieri M, Mirande C, Oliver A, Moons P, Goossens H, et al. *Pseudomonas aeruginosa*: a clinical and genomics update. *FEMS Microbiol Rev.* 2021 Nov 1 ;45(6).
9. Oliver A, Mulet X, López-Causapé C, Juan C. The increasing threat of *Pseudomonas aeruginosa* high-risk clones. *Drug Resist Updat.* 2015 Jul 1 ;21–22:41–59.
10. del Barrio-Tofiño E, López-Causapé C, Oliver A. *Pseudomonas aeruginosa* epidemic high-risk clones and their association with horizontally-acquired β -lactamases: 2020 update. *Int J Antimicrob Agents.* 2020 Dec 1 ;56(6).
11. Treepong P, Kos VN, Guyeux C, Blanc DS, Bertrand X, Valot B, et al. Global emergence of the widespread *Pseudomonas aeruginosa* ST235 clone. *Clin Microbiol Infect.* 2018 Mar 1 ;24(3):258–66.
12. Del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, López-Causapé C, Sánchez-Diener I, Cabot G, et al. Spanish nationwide survey on

- Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. *J Antimicrob Chemother.* 2019 Jul 1 ;74(7):1825–35.
13. Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, et al. The resistome of *Pseudomonas aeruginosa* in relationship to phenotypic susceptibility. *Antimicrob Agents Chemother.* 2015 Jan 1 ;59(1):427–36.
 14. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ, Zamorano L, et al. Deciphering the Resistome of the Widespread *Pseudomonas aeruginosa* Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. *Antimicrob Agents Chemother.* 2016 Dec 1 ;60(12):7415–23.
 15. Jaillard M, van Belkum A, Cady KC, Creely D, Shortridge D, Blanc B, et al. Correlation between phenotypic antibiotic susceptibility and the resistome in *Pseudomonas aeruginosa*. *Int J Antimicrob Agents.* 2017 Aug 1 ;50(2):210–8.
 16. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? *Clin Microbiol Infect.* 2017 Oct 1 ;23(10):704–12.
 17. Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L. New β -Lactam- β -Lactamase Inhibitor Combinations. *Clin Microbiol Rev.* 2020 Jan 1 ;34(1):1–61.
 18. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect Dis.* 2021 Feb 1 ;21(2):226–40.
 19. Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. *Ann Intensive Care.* 2023 Dec 1 ;13(1).
 20. Fraile-Ribot PA, Cabot G, Mulet X, Periañez L, Luisa Martín-Pena M, Juan C, et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* 2018 Mar 1 ;73(3):658–63.
 21. Mojica MF, De La Cadena E, García-Betancur JC, Porras J, Novoa-Cacedo I, Páez-Zamora L, et al. Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and *Pseudomonas aeruginosa* in Latin American Hospitals. *mSphere.* 2023 Apr 20 ;8(2).
 22. Alonso-García I, Vázquez-Ucha JC, Lasarte-Monterrubio C, González-Mayo E, Lada-Salvador P, Vela-Fernández R, et al. Simultaneous and divergent evolution of resistance to cephalosporin/ β -lactamase inhibitor

- combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR *Pseudomonas aeruginosa* infections. *J Antimicrob Chemother.* 2023 May 1 ;78(5):1195–200.
23. Gomis-Font MA, Pitart C, del Barrio-Tofiño E, Zboromyrska Y, Cortes-Lara S, Mulet X, et al. Emergence of Resistance to Novel Cephalosporin- β -Lactamase Inhibitor Combinations through the Modification of the *Pseudomonas aeruginosa* MexCD-OprJ Efflux Pump. *Antimicrob Agents Chemother.* 2021 Aug 1 ;65(8).
 24. Shields RK, Stellfox ME, Kline EG, Samanta P, Van Tyne D. Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant *Pseudomonas aeruginosa* Pneumonia. *Clin Infect Dis.* 2022 Aug 15 ;75(4):710–4.
 25. Bahr G, González LJ, Vila AJ. Metallo- β -lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design. *Chem Rev.* 2021 Jul 14 ;121(13):7957–8094.
 26. Ruedas-López A, Alonso-García I, Lasarte-Monterrubbio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, et al. Selection of AmpC β -Lactamase Variants and Metallo- β -Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR *Pseudomonas aeruginosa* Infections. *Antimicrob Agents Chemother.* 2022 Feb 1 ;66(2).
 27. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Vol. 22, *Clinical Microbiology Reviews.* American Society for Microbiology (ASM); 2009. p. 582–610.
 28. Juan C, Torrens G, González-Nicolau M, Oliver A. Diversity and regulation of intrinsic β -lactamases from non-fermenting and other Gram-negative opportunistic pathogens. *FEMS Microbiol Rev.* 2017 Nov 1 ;41(6):781–815.
 29. Juan C, Maciá MD, Gutiérrez O, Vidal C, Pérez JL, Oliver A. Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in *Pseudomonas aeruginosa* clinical strains. *Antimicrob Agents Chemother.* 2005 Nov ;49(11):4733–8.
 30. Moya B, Dötsch A, Juan C, Blázquez J, Zamorano L, Haussler S, et al. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. *PLoS Pathog.* 2009 ;5(3).
 31. Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyá B, Juan C, et al. *Pseudomonas aeruginosa* ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. *Antimicrob Agents Chemother.* 2014 ;58(6):3091–9.
 32. Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. Avibactam and class C β -lactamases: mechanism of inhibition,

- conservation of the binding pocket, and implications for resistance. *Antimicrob Agents Chemother.* 2014 Oct 1 ;58(10):5704–13.
33. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant *Pseudomonas aeruginosa* Infections: Clinical Effectiveness and Evolution of Resistance. *Clin Infect Dis.* 2017 Jul 1 ;65(1):110–20.
34. Berrazeg M, Jeannot K, Ntsogo Enguéné VY, Broutin I, Loeffert S, Fournier D, et al. Mutations in β -Lactamase AmpC Increase Resistance of *Pseudomonas aeruginosa* Isolates to Antipseudomonal Cephalosporins. *Antimicrob Agents Chemother.* 2015 Oct 1 ;59(10):6248–55.
35. Gomis-Font MA, Sastre-Femenia MÀ, Taltavull B, Cabot G, Oliver A. In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* 2023 Jul 5 ;78(7):1785–94.
36. Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, et al. Beta-lactamase database (BLDB) - structure and function. *J Enzyme Inhib Med Chem.* 2017 Jan 1;32(1):917–9.
37. Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Pérez JL, et al. In Vivo Emergence of Resistance to Novel Cephalosporin- β -Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β -Lactamase (OXA-539) in Sequence Type 235 *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2017 Sep 1 ;61(9).
38. Arca-Suárez J, Lasarte-Monterrubbio C, Rodiño-Janeiro BK, Cabot G, Vázquez-Ucha JC, Rodríguez-Iglesias M, et al. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR *Pseudomonas aeruginosa* infections. *J Antimicrob Chemother.* 2021 ;76(1):91–100.
39. Lasarte-Monterrubbio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I, et al. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* 2022 Oct 1 ;77(10):2809–15.
40. Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, et al. Global epidemiology and clinical outcomes of carbapenem-resistant *Pseudomonas aeruginosa* and associated carbapenemases (POP): a prospective cohort study. *Lancet Microbe.* 2023 Mar 1 ;4(3):e159–70.
41. Wang MG, Liu ZY, Liao XP, Sun RY, Li RB, Liu Y, et al. Retrospective Data Insight into the Global Distribution of Carbapenemase-Producing *Pseudomonas aeruginosa*. *Antibiotics (Basel).* 2021 May 1 ;10(5).
42. Fortunato G, Vaz-Moreira I, Gajic I, Manaia CM. Insight into phylogenomic bias of blaVIM-2 or blaNDM-1 dissemination amongst carbapenem-

- resistant *Pseudomonas aeruginosa*. *Int J Antimicrob Agents*. 2023 May 1 ;61(5).
43. Torrens G, Van Der Schalk TE, Cortes-Lara S, Timbermont L, Del Barrio-Tofiño E, Xavier BB, et al. Susceptibility profiles and resistance genomics of *Pseudomonas aeruginosa* isolates from European ICUs participating in the ASPIRE-ICU trial. *J Antimicrob Chemother*. 2022 Jul 1 ;77(7):1862–72.
 44. Àngel Sastre-Femenia M, Fernández-Muñoz A, Gomis-Font MA, Taltavull B, López-Causapé C, Arca-Suárez J, et al. *Pseudomonas aeruginosa* antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis. *The Lancet Regional Health - Europe*. 2023;34:100736.
 45. Takemura M, Wise MG, Hackel MA, Sahm DF, Yamano Y. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019). *J Antimicrob Chemother*. 2023 Aug 2 ;78(8).
 46. Le Terrier C, Nordmann P, Poirel L. In vitro activity of aztreonam in combination with newly developed β -lactamase inhibitors against MDR Enterobacterales and *Pseudomonas aeruginosa* producing metallo- β -lactamases. *J Antimicrob Chemother* 2022 Jan 1;78(1):101–7.
 47. Le Terrier C, Nordmann P, Freret C, Seigneur M, Poirel L. Impact of Acquired Broad Spectrum β -Lactamases on Susceptibility to Novel Combinations Made of β -Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β -Lactamase Inhibitors in *Escherichia coli* and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2023 Jul 1;67(7).
 48. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, et al. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent “ β -Lactam Enhancer” Activity against *Pseudomonas aeruginosa*, Including Multidrug-Resistant Metallo- β -Lactamase-Producing High-Risk Clones. *Antimicrob Agents Chemother*. 2017 Jun 1 ;61(6).
 49. Meletiadiis J, Paranos P, Georgiou PC, Vourli S, Antonopoulou S, Michelaki A, et al. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against *Klebsiella pneumoniae* and cefepime against *Pseudomonas aeruginosa* metallo-beta-lactamase-producing clinical isolates. *Int J Antimicrob Agents*. 2021 Nov 1 ;58(5).
 50. Poirel L, De la Rosa JMO, Sadek M, Nordmann P. Impact of Acquired Broad-Spectrum β -Lactamases on Susceptibility to Cefiderocol and Newly Developed β -Lactam/ β -Lactamase Inhibitor Combinations in *Escherichia coli* and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2022 Apr 1 ;66(4).

- 866 51. Shortridge D, Carvalhaes C, Deshpande L, Castanheira M. Activity of
867 meropenem/vaborbactam and comparators against Gram-negative
868 isolates from Eastern and Western European patients hospitalized with
869 pneumonia including ventilator-associated pneumonia (2014-19). J
870 Antimicrob Chemother. 2021 Oct 1 ;76(10):2600–5.
- 871 52. Mushtaq S, Meunier D, Vickers A, Woodford N, Livermore DM. Activity of
872 imipenem/relebactam against *Pseudomonas aeruginosa* producing ESBLs
873 and carbapenemases. J Antimicrob Chemother. 2021 Feb 1 ;76(2):434–
874 42.
- 875 53. Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-
876 Diener I, Cortes-Lara S, et al. Activity of Imipenem-Relebactam against a
877 Large Collection of *Pseudomonas aeruginosa* Clinical Isolates and
878 Isogenic β -Lactam-Resistant Mutants. Antimicrob Agents Chemother.
879 2020 Jan 27 ;64(2).
- 880 54. Fraile-Ribot PA, Fernández J, Gomis-Font MA, Forcelledo L, Mulet X,
881 López-Causapé C, et al. In Vivo Evolution of GES β -Lactamases Driven
882 by Ceftazidime/Avibactam Treatment of *Pseudomonas aeruginosa*
883 Infections. Antimicrob Agents Chemother. 2021 Sep 1 ;65(9).
- 884 55. Faccone D, de Mendieta JM, Albornoz E, Chavez M, Genero F, Echegorry
885 M, et al. Emergence of KPC-31, a KPC-3 Variant Associated with
886 Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant
887 ST235 *Pseudomonas aeruginosa* Clinical Isolate. Antimicrob Agents
888 Chemother. 2022 Nov 1 ;66(11).
- 889 56. Recio R, Villa J, González-Bodí S, Brañas P, Orellana MÁ, Mancheño-
890 Losa M, et al. Genomic Analysis of Ceftazidime/Avibactam-Resistant
891 GES-Producing Sequence Type 235 *Pseudomonas aeruginosa* Isolates.
892 Antibiotics (Basel). 2022 Jul 1 ;11(7).
- 893 57. Bonnin RA, Bogaerts P, Girlich D, Huang TD, Dortet L, Glupczynski Y, et
894 al. Molecular Characterization of OXA-198 Carbapenemase-Producing
895 *Pseudomonas aeruginosa* Clinical Isolates. Antimicrob Agents Chemother.
896 2018 Jun 1 ;62(6).
- 897 58. Chen W, Zhang YM, Davies C. Penicillin-Binding Protein 3 Is Essential for
898 Growth of *Pseudomonas aeruginosa*. Antimicrob Agents Chemother. 2016
899 Jan 1 ;61(1).
- 900 59. Caballero JD, Clark ST, Coburn B, Zhang Y, Wang PW, Donaldson SL, et
901 al. Selective Sweeps and Parallel Pathoadaptation Drive *Pseudomonas*
902 *aeruginosa* Evolution in the Cystic Fibrosis Lung. mBio. 2015 ;6(5).
- 903 60. López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA,
904 Johansen HK, et al. Evolution of the *Pseudomonas aeruginosa* mutational
905 resistome in an international Cystic Fibrosis clone. Sci Rep. 2017 Dec 1
906 ;7(1).
- 907 61. Cabot G, Zamorano L, Moyà B, Juan C, Navas A, Blázquez J, et al.
908 Evolution of *Pseudomonas aeruginosa* Antimicrobial Resistance and

- Fitness under Low and High Mutation Rates. *Antimicrob Agents Chemother.* 2016 Mar 1 ;60(3):1767–78.
62. Han S, Zaniewski RP, Marr ES, Lacey BM, Tomaras AP, Evdokimov A, et al. Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A.* 2010 Dec 21 ;107(51):22002–7.
63. Jorth P, McLean K, Ratjen A, Secor PR, Bautista GE, Ravishankar S, et al. Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in *Pseudomonas aeruginosa*. *mBio.* 2017 Sep 1 ;8(5).
64. Cabot G, Florit-Mendoza L, Sánchez-Diener I, Zamorano L, Oliver A. Deciphering β -lactamase-independent β -lactam resistance evolution trajectories in *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* 2018 Dec 1 ;73(12):3322–31.
65. Barceló I, Cabot G, Palwe S, Joshi P, Takalkar S, Periasamy H, et al. In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in *Pseudomonas aeruginosa*: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy. *J Antimicrob Chemother.* 2021 Oct 1 ;76(10):2546–57.
66. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev.* 2009 Oct ;22(4):582–610
67. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible *Pseudomonas aeruginosa* collected during 2009-11 in 14 European and Mediterranean countries. *J Antimicrob Chemother.* 2014 ;69(7):1804–14.
68. Richardot C, Plésiat P, Fournier D, Monlezun L, Broutin I, Llanes C. Carbapenem resistance in cystic fibrosis strains of *Pseudomonas aeruginosa* as a result of amino acid substitutions in porin OprD. *Int J Antimicrob Agents.* 2015 May 1 ;45(5):529–32.
69. Ocampo-Sosa AA, Cabot G, Rodríguez C, Roman E, Tubau F, Macia MD, et al. Alterations of OprD in carbapenem-intermediate and -susceptible strains of *Pseudomonas aeruginosa* isolated from patients with bacteremia in a Spanish multicenter study. *Antimicrob Agents Chemother.* 2012 Apr ;56(4):1703–13.
70. Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin Microbiol Rev.* 2015 ;28(2):337–418
71. Gomis-Font MA, Cabot G, Sánchez-Diener I, Fraile-Ribot PA, Juan C, Moya B, et al. In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* 2020 Sep 1 ;75(9):2508–15.

- 952 72. Gomis-Font MA, Cabot G, López-Argüello S, Zamorano L, Juan C, Moyá
953 B, et al. Comparative analysis of in vitro dynamics and mechanisms of
954 ceftolozane/tazobactam and imipenem/relebactam resistance
955 development in *Pseudomonas aeruginosa* XDR high-risk clones. *J*
956 *Antimicrob Chemother.* 2022 Apr 1 ;77(4):957–68.
- 957 73. Sanz-García F, Hernando-Amado S, Martínez JL. Mutation-Driven
958 Evolution of *Pseudomonas aeruginosa* in the Presence of either
959 Ceftazidime or Ceftazidime-Avibactam. *Antimicrob Agents Chemother.*
960 2018 Oct 1 ;62(10).
- 961 74. Hocquet D, Petitjean M, Rohmer L, Valot B, Kulasekara HD, Bedel E, et
962 al. Pyomelanin-producing *Pseudomonas aeruginosa* selected during
963 chronic infections have a large chromosomal deletion which confers
964 resistance to pyocins. *Environ Microbiol.* 2016 Oct 1 ;18(10):3482–93.
- 965 75. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler
966 S. Genomewide identification of genetic determinants of antimicrobial drug
967 resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.*
968 2009 Jun ;53(6):2522–31.
- 969 76. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock REW, Martínez JL.
970 Genetic determinants involved in the susceptibility of *Pseudomonas*
971 *aeruginosa* to beta-lactam antibiotics. *Antimicrob Agents Chemother.* 2010
972 Oct ;54(10):4159–67.
- 973 77. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in
974 *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: Mechanisms and
975 epidemiology. *Int J Antimicrob Agents.* 2015 May 16 ;45(6):568–85.
- 976 78. Costello SE, Deshpande LM, Davis AP, Mendes RE, Castanheira M.
977 Aminoglycoside-modifying enzyme and 16S ribosomal RNA
978 methyltransferase genes among a global collection of Gram-negative
979 isolates. *J Glob Antimicrob Resist.* 2019 Mar 1 ;16:278–85.
- 980 79. Yokoyama K, Doi Y, Yamane K, Kurokawa H, Shibata N, Shibayama K, et
981 al. Acquisition of 16S rRNA methylase gene in *Pseudomonas aeruginosa*.
982 *Lancet.* 2003 Dec 6 ;362(9399):1888–93.
- 983 80. Choi YJ, Kim YA, Junglim K, Jeong SH, Shin JH, Shin KS, et al.
984 Emergence of NDM-1-producing *Pseudomonas aeruginosa* Sequence
985 Type 773 Clone: Shift of Carbapenemase Molecular Epidemiology and
986 Spread of 16S rRNA Methylase Genes in Korea. *Ann Lab Med.* 2023 Mar
987 1;43(2):196–9.
- 988 81. Mc Gann PT, Lebreton F, Jones BT, Dao HD, Martin MJ, Nelson MJ, et al.
989 Six Extensively Drug-Resistant Bacteria in an Injured Soldier, Ukraine.
990 *Emerg Infect Dis.* 2023 Aug 1;29(8):1692–5.
- 991 82. Guénard S, Muller C, Monlezun L, Benas P, Broutin I, Jeannot K, et al.
992 Multiple mutations lead to MexXY-OprM-dependent aminoglycoside
993 resistance in clinical strains of *Pseudomonas aeruginosa*. *Antimicrob*
994 *Agents Chemother.* 2014 Jan ;58(1):221–8.

83. Prickett MH, Hauser AR, McColley SA, Cullina J, Potter E, Powers C, et al. Aminoglycoside resistance of *Pseudomonas aeruginosa* in cystic fibrosis results from convergent evolution in the *mexZ* gene. *Thorax*. 2017 Jan 1 ;72(1):40–7.
84. El'Garch F, Jeannot K, Hocquet D, Llanes-Barakat C, Plésiat P. Cumulative effects of several nonenzymatic mechanisms on the resistance of *Pseudomonas aeruginosa* to aminoglycosides. *Antimicrob Agents Chemother*. 2007 Mar ;51(3):1016–21.
85. Schurek KN, Marr AK, Taylor PK, Wiegand I, Semenec L, Khaira BK, et al. Novel genetic determinants of low-level aminoglycoside resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2008 Dec ;52(12):4213–9.
86. Feng Y, Jonker MJ, Moustakas I, Brul S, Ter Kuile BH. Dynamics of Mutations during Development of Resistance by *Pseudomonas aeruginosa* against Five Antibiotics. *Antimicrob Agents Chemother*. 2016 Jul 1 ;60(7):4229–36.
87. Chung JCS, Becq J, Fraser L, Schulz-Trieglaff O, Bond NJ, Foweraker J, et al. Genomic variation among contemporary *Pseudomonas aeruginosa* isolates from chronically infected cystic fibrosis patients. *J Bacteriol*. 2012 Sep ;194(18):4857–66.
88. Markussen T, Marvig RL, Gómez-Lozano M, Aanæs K, Burleigh AE, Høiby N, et al. Environmental heterogeneity drives within-host diversification and evolution of *Pseudomonas aeruginosa*. *mBio*. 2014 Sep 16 ;5(5).
89. Greipel L, Fischer S, Klockgether J, Dorda M, Mielke S, Wiehlmann L, et al. Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of *Pseudomonas aeruginosa* Isolates from Airways of Cystic Fibrosis Patients. *Antimicrob Agents Chemother*. 2016 Nov 1 ;60(11):6726–34.
90. Bolard A, Plésiat P, Jeannot K. Mutations in Gene *fusA1* as a Novel Mechanism of Aminoglycoside Resistance in Clinical Strains of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2018 Feb ;62(2).
91. Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S. Quantitative contributions of target alteration and decreased drug accumulation to *Pseudomonas aeruginosa* fluoroquinolone resistance. *Antimicrob Agents Chemother*. 2013 Mar ;57(3):1361–8.
92. Belotti PT, Thabet L, Laffargue A, André C, Coulange-Mayonnove L, Arpin C, et al. Description of an original integron encompassing *blaVIM-2*, *qnrVC1* and genes encoding bacterial group II intron proteins in *Pseudomonas aeruginosa*. *J Antimicrob Chemother*. 2015 Aug 1 ;70(8):2237–40.
93. Pérez-Vázquez M, Sola-Campoy PJ, Zurita ÁM, Ávila A, Gómez-Bertomeu F, Solís S, et al. Carbapenemase-producing *Pseudomonas aeruginosa* in Spain: interregional dissemination of the high-risk clones ST175 and

- ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. *Int J Antimicrob Agents*. 2020 Jul 1 ;56(1).
94. Shortridge D, Gales AC, Streit JM, Huband MD, Tsakris A, Jones RN. Geographic and Temporal Patterns of Antimicrobial Resistance in *Pseudomonas aeruginosa* Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016. *Open Forum Infect Dis*. 2019 Mar 15 ;6(Suppl 1):S63–8.
 95. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol*. 2014 ;5(NOV). Available from: <https://pubmed.ncbi.nlm.nih.gov/25505462/>
 96. Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. *Int J Antimicrob Agents*. 2017 May 1 ;49(5):526–35.
 97. Barrow K, Kwon DH. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2009 Dec ;53(12):5150–4.
 98. Muller C, Plésiat P, Jeannot K. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β -lactams in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2011 Mar ;55(3):1211–21.
 99. Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, et al. Polymyxin resistance of *Pseudomonas aeruginosa* phoQ mutants is dependent on additional two-component regulatory systems. *Antimicrob Agents Chemother*. 2013 May ;57(5):2204–15.
 100. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, et al. PmrB mutations promote polymyxin resistance of *Pseudomonas aeruginosa* isolated from colistin-treated cystic fibrosis patients. *Antimicrob Agents Chemother*. 2012 Feb ;56(2):1019–30.
 101. Döbelmann B, Willmann M, Steglich M, Bunk B, Nübel U, Peter S, et al. Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant *Pseudomonas aeruginosa* during Morbidostat Culture. *Antimicrob Agents Chemother*. 2017 Sep 1 ;61(9).
 102. Cervoni M, Sposato D, Lo Sciuto A, Imperi F. Regulatory Landscape of the *Pseudomonas aeruginosa* Phosphoethanolamine Transferase Gene *eptA* in the Context of Colistin Resistance. *Antibiotics (Basel)*. 2023 Feb 1 ;12(2).
 103. Snesrud E, Maybank R, Kwak YI, Jones AR, Hinkle MK, McGann P. Chromosomally Encoded *mcr-5* in Colistin-Nonsusceptible *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2018 Aug 1 ;62(8).
 104. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. *Int J Infect Dis*. 2011 Nov ;15(11).
 105. Castañeda-García A, Rodríguez-Rojas A, Guelfo JR, Blázquez J. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in *Pseudomonas aeruginosa*. *J Bacteriol*. 2009 Nov ;191(22):6968–74.

106. Rodríguez-Rojas A, Maciá MD, Couce A, Gómez C, Castañeda-García A, Oliver A, et al. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for *P. aeruginosa* infections. *PLoS One*. 2010 ;5(4).
107. Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, et al. Genomics and Susceptibility Profiles of Extensively Drug-Resistant *Pseudomonas aeruginosa* Isolates from Spain. *Antimicrob Agents Chemother*. 2017 Nov 1 ;61(11).
108. Silveira MC, Rocha-de-Souza CM, de Oliveira Santos IC, Pontes L da S, Oliveira TRT e., Tavares-Teixeira CB, et al. Genetic Basis of Antimicrobial Resistant Gram-Negative Bacteria Isolated From Bloodstream in Brazil. *Front Med (Lausanne)*. 2021 Mar 15 ;8.
109. Takahashi T, Tada T, Shrestha S, Hishinuma T, Sherchan JB, Tohya M, et al. Molecular characterisation of carbapenem-resistant *Pseudomonas aeruginosa* clinical isolates in Nepal. *J Glob Antimicrob Resist*. 2021 Sep 1;26:279–84.
110. Lebreton F, Snesrud E, Hall L, Mills E, Galac M, Stam J, et al. A panel of diverse *Pseudomonas aeruginosa* clinical isolates for research and development. *JAC Antimicrob Resist*. 2021 Dec 1 ;3(4).
111. Cejas D, Elena A, González-Espinosa FE, Pallecchi L, Vay C, Rossolini GM, et al. Characterisation of blaKPC-2-harbouring plasmids recovered from *Pseudomonas aeruginosa* ST654 and ST235 high-risk clones. *J Glob Antimicrob Resist*. 2022 Jun 1;29:310–2.
112. Pincus NB, Bachta KER, Ozer EA, Allen JP, Pura ON, Qi C, et al. Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed *Pseudomonas aeruginosa* Clonal Complex 446 in an Academic Medical Center. *Clin Infect Dis*. 2020 Sep 15 ;71(6):1524–31.
113. Hu Y, Peng W, Wu Y, Li H, Wang Q, Yi H, et al. A Potential High-Risk Clone of *Pseudomonas aeruginosa* ST463. *Front Microbiol*. 2021 May 28 ;12.
114. Martak D, Gbaguidi-Haore H, Meunier A, Valot B, Conzelmann N, Eib M, et al. High prevalence of *Pseudomonas aeruginosa* carriage in residents of French and German long-term care facilities. *Clin Microbiol Infect*. 2022 Oct 1 ;28(10):1353–8.
115. Fonseca ÉL, Morgado SM, Caldart R V., Freitas F, Vicente ACP. Emergence of a VIM-2-producing extensively drug-resistant (XDR) *Pseudomonas aeruginosa* ST309 in South America: a comparative genomic analysis. *Int J Antimicrob Agents*. 2022 Feb 1 ;59(2).
116. Chilam J, Argimón S, Limas MT, Masim ML, Gayeta JM, Lagrada ML, et al. Genomic surveillance of *Pseudomonas aeruginosa* in the Philippines, 2013-2014. *Western Pac Surveill Response J*. 2021 Apr 1 ;12(2).
117. Morales-Espinosa R, Delgado G, Espinosa LF, Isselo D, Méndez JL, Rodríguez C, et al. Fingerprint Analysis and Identification of Strains ST309 as a Potential High Risk Clone in a *Pseudomonas aeruginosa* Population

- Isolated from Children with Bacteremia in Mexico City. *Front Microbiol.* 2017 Mar 1 ;8(MAR).
118. Khan A, Tran TT, Rios R, Hanson B, Shropshire WC, Sun Z, et al. Extensively Drug-Resistant *Pseudomonas aeruginosa* ST309 Harboring Tandem Guiana Extended Spectrum β -Lactamase Enzymes: A Newly Emerging Threat in the United States. *Open Forum Infect Dis.* 2019 Jul 1 ;6(7).
119. Cortes-Lara S, Barrio-Tofiño E del, López-Causapé C, Oliver A, Martínez-Martínez L, Bou G, et al. Predicting *Pseudomonas aeruginosa* susceptibility phenotypes from whole genome sequence resistome analysis. *Clin Microbiol Infect.* 2021 Nov 1 ;27(11):1631–7.
120. Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo T, Oliver A, et al. Predicting antimicrobial resistance in *Pseudomonas aeruginosa* with machine learning-enabled molecular diagnostics. *EMBO Mol Med.* 2020 Mar 6 ;12(3).
121. Cabot G, Lara-Esbrí P, Mulet X, Oliver A. Whole-genome sequence-guided PCR for the rapid identification of the *Pseudomonas aeruginosa* ST175 high-risk clone directly from clinical samples. *J Antimicrob Chemother.* 2021 Apr 1 ;76(4):945–9.

Table 1. Main resistance mechanisms to classical and novel antibiotics in *Pseudomonas aeruginosa*

Antipseudomonal categories	Antipseudomonal agents	Main mutational resistance mechanisms	Alternative mutational resistance mechanisms	Mutational resistance on horizontally acquired determinants	Horizontally-acquired resistance mechanisms
Penicillins + β -lactamase inhibitors	Piperacillin/tazobactam	AmpC $\uparrow$	PBP3, GalU		ESBLs, class A and B carbapenemases
Cephalosporins	Ceftazidime	AmpC $\uparrow$	PBP3, GalU	OXA-2/10	ESBLs, class A and B carbapenemases
	Cefepime	MexXY $\uparrow$, AmpC $\uparrow$	PBP3, GalU	OXA-2/10	ESBLs, class A and B carbapenemases
Monobactams	Aztreonam	MexAB $\uparrow$, AmpC $\uparrow$	PBP3, GalU	OXA-2/10	ESBLs and class A carbapenemases
Carbapenems	Imipenem	OprD-	MexST, PBP2, PBP1a		Class A and B carbapenemases
	Meropenem	OprD-, MexAB $\uparrow$	PBP3, GalU		Class A and B carbapenemases
Fifth generation cephalosporins+ classical β -lactamase inhibitors	Ceftolozane/tazobactam	AmpC Ω -loop	PBP3, GalU Efflux pumps	OXA-2/10	ESBLs, class A and B carbapenemases
Cephalosporins + diazabicycloctanes β -lactamase inhibitors	Ceftazidime/avibactam	AmpC Ω -loop, MexAB $\uparrow$	PBP3, GalU	OXA-2/10, GES, KPC	Class B carbapenemases
carbapenems + diazabicycloctanes β -lactamase inhibitors	Imipenem/relebactam	OprD-, MexAB $\uparrow^{**}$	MexST, ParRS PBP2, PBP1a		Class A and B carbapenemases
carbapenems + boronic acid β -lactamase inhibitors	Meropenem/vaborbactam	OprD-, MexAB $\uparrow$	PBP3, GalU		Class A and B carbapenemases
Siderophore cephalosporins	Cefiderocol	Iron transporters, AmpC Ω -loop	PBP3, GalU	OXA-2/10 **	ESBLs, class A and B carbapenemases **
Monobactams + diazabicycloctanes β -lactamase inhibitors	Aztreonam/avibactam*	MexAB $\uparrow$	PBP3, GalU		ESBLs and class A carbapenemases **
Cephalosporins+	Cefepime/zidebactam*	MexXY $\uparrow$, MexAB $\uparrow$	PBP3, GalU		ESBLs, class A and B

diazabicycloctanes β -lactamase and PBP2 inhibitors			PBP2		carbapenemases**
cephalosporins+ boronic acid β -lactamase inhibitors including MBLs	Cefepime/taniborbactam*	MexXY $\uparrow$, MexAB $\uparrow$	PBP3, GalU		IMPs
Fluoroquinolones	Ciprofloxacin, levofloxacin	QRDR	MexAB/XY/CD/EF $\uparrow$		Qnr
Aminoglycosides	Tobramycin, amikacin	MexXY $\uparrow$ **	FusA1		Aminoglycoside modifying enzymes, 16S rRNA methylases
Polymyxins	Colistin, polymyxin B	PmrAB/PhoPQ/ParRS			MCR (Very uncommon)
Fosfonic acids	Fosfomicin	GlpT			FosA

* Not yet approved

**Low level resistance. Clinical resistance requires additional mechanisms

$\uparrow$ Hyperproduction

Journal Pre-proof

Antibiotic	AmpC ↑	MexAB↑	OprD-	AmpC Ω-	OXA	ESBL	CarbA	CarbA Mut**	CarbB	Iron transp.
	Journal Pre-proof									
Piperacillin/tazobactam	R	r	S	S/r	R	R	R	R	R	S
Ceftazidime	R	r	S	R	R	R	R	R	R	S
Cefepime	r/R	r/R	S	R	R	R	R	R	R	S
Aztreonam	r/R	R	S	R	r/R	R	R	R	S	S
Imipenem	S	S	r/R	S	S	S	R	S	R	S
Meropenem	S	r	r	S	S	S	R	S	R	S
Ceftolozane/tazobactam	S	S	S	R	R	r/R	R	R	R	S
Ceftazidime/avibactam	S/r	r	S	r/R	r/R	S/r	S	R	R	S
Meropenem/vaborbactam	S	r	r	S	S	S	r/R	S	R	S
Imipenem/relebactam	S	r	r	S	S	S	r/R	S	R	S
Cefiderocol	S	S	S	S/r	S/r	S/r	S/r	S/r	S/r	r
Aztreonam/avibactam	S	R	S	r/R	r/R	S/r	S/r	r/R	S	S
Cefepime/zidebactam	S	r/R	S	S/r	S/r	S/r	S/r	S/r	r/R	S
Cefepime/taniborbactam	S	r/R	S	S/r	S/r	S/r	S/r	S/r	r/R	S

Figure 1. Antimicrobial spectrum expected for classical and novel β -lactams and β -lactam- β -lactamase inhibitor combinations against most relevant *P. aeruginosa* resistance mechanisms when present alone in clinical strains. To reduce complexity, combinations of resistance mechanisms are not considered, but acknowledged to be frequent among clinical strains. S (green), fully susceptible; r (orange), reduced susceptibility; R (red) clinical resistance. For some antibiotics-mechanisms combinations a range of effect S/r or r/R is considered depending on the specific mechanism or mutation; in such cases, the specific color chosen was that of the most likely phenotype. It is noted however, that variation in the quantitative effect on resistance does occur according to the specific nature of the mechanisms or their expression. * AmpC (PDC) variants associated with ceftolozane/tazobactam and/or ceftazidime/avibactam resistance. **KPC or GES mutations associated with ceftazidime/avibactam resistance and collateral carbapenem susceptibility.

ST	Clonal Complex	O-antigen Serotype	T3SS	CONTINENT						CARBAPENEMASE							
				N. America	S. America	Europe	Africa	Asia	Oceania	<i>bla</i> GES	<i>bla</i> KPC	<i>bla</i> FIM	<i>bla</i> GIM	<i>bla</i> IMP	<i>bla</i> NDM	<i>bla</i> SPM	<i>bla</i> VIM
ST235	CC235	O11	ExoU+														
ST111	CC111	O12 (O4)	ExoS+														
ST233	CC233	O6	ExoS+														
ST244	CC244	O2	ExoS+														
ST357	CC357	O11	ExoU+														
ST308	CC308	O11	ExoU+														
ST175	CC175	O4	ExoS+														
ST277	CC277	O2	ExoS+														
ST654	CC654	O11	ExoS+														
ST298	CC446	O11	ExoU+														

Figure 2. Summary of the main characteristics of the top 10 *P. aeruginosa* high-risk clones. Updated in July 2023 from Del Barrio-Tofiño 2020 (10). Novel descriptions since 2020 are shown in red.